Infliximab and Anti-Infliximab Antibody, DoseASSURE™ IFX
Also known as: Anti-TNF-alpha Drug, DoseASSURE, IFD, Remicade
Use
Provides infliximab drug concentration levels as well as levels of anti-infliximab antibodies.
Special Instructions
Patients are advised to discontinue biotin supplements at least 72 hours before sample collection to avoid interference in the assay. For multiple tests on frozen samples, submit separate frozen specimens for each test to avoid delays in turnaround time.
Limitations
The presence of anti-infliximab antibodies does not guarantee a failure of infliximab therapy, and their absence does not guarantee treatment success. High serum biotin concentrations may interfere with the assay. Assay failure to detect infliximab or anti-infliximab antibodies could be due to factors not related to therapeutic failure or antibody presence.
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 39803-2
- 39803-2
- 72623-2
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
1 mL
Container
Red-top tube, gel-barrier tube
Collection Instructions
Send serum in a plastic transport tube.
Patient Preparation
Patients may be advised to stop biotin consumption at least 72 hours prior to sample collection.
Storage Instructions
Frozen (preferred) or refrigerated
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 7 days |
| Frozen | 359 days |
Other tests from different labs that may be relevant